{"Pharmacology": {"Pharmacodynamics": {"Mechanism of action": ["Serotonin Receptor Modulation in SSRI Treatment", "Impact of SSRIs on Neurogenesis", "SSRIs Effect on Neural Processing of Emotional Cues", "Paroxetine Binding", "SSRIs Effect on Fear", "Structural Basis of Serotonin Transporter Inhibition by SSRIs", "SSRIs and Inflammation", "SSRIs Effects on Neuroendocrine System", "SSRIs for Substance Abuse (Cocaine)", "SSRIs Effects on Ion Channels", "SSRIs Effects on Antimicrobials and Gut Microbiome", "Astrocyte Receptors as a Target for SSRIs", "Repeated SSRIs Exposures Effects on Dopamine Receptors", "SSRIs in Model Organisms ( C. Elegans and Drosophilia)", "Predicting SSRI Response in Depression via miRNA and BDNF", "SSRIs Effect on Reinforcement Learning in Rodents", "Neurochemical and Electrophysiological Correlates of SSRIs", "SSRIs Effect on Brain-derived Neurotrophic Factor (BDNF) Levels in Depressive Patients", "Paroxetines Therapeutic Potential as G Protein-coupled Receptor Kinase 2 (GRK2) Inhibitor for Cardiovascular Diseases", "Loudness Dependence of Auditory Evoked Potentials (LDAEP) as Biomarker for Depression", "Tryptophan Depletion in Depression"], "Animal Models of Disorders": ["The Chronic Unpredictable Mild Stress Model of Depression", "SSRIs in Forced Swimming Test", "Olfactory Bulbectomized (OB) Rat Model of Depression"], "Other": ["SSRIs Effect on Pulmonary Hypertension", "SRRIs and Ocular Safety"]}, "Pharmacokinetics": ["SSRIs and the Cytochrome P450 System", "(Sertraline) Drug Delivery"], "Pharmacogenetics": ["Serotonin Transporter Gene and Antidepressant Response", "Genotype Mediated Response to SSRIs"], "Analytical Methods": ["Quantification of SSRIs in Biological Samples", "Novel Compounds Synthesis and Antidepressant Potential"], "Other": ["Risks of Prenatal Exposure", "SSRI Synthesis", "Methylenedioxymethamphetamine (MDMA) Induced Neurotoxicity", "SSRIs Effect on Male Fertility"]}, "Indications": {"Disorders": {"Depressive Disorders": ["The Chronic Unpredictable Mild Stress Model of Depression", "Fluvoxamine for Depression", "Pediatric Depression", "SSRIs in Forced Swimming Test", "Sequenced Depression Treatment", "Serotonin Transporter Gene and Antidepressant Response", "Post-Stroke SSRI Use", "SSRIs for Bipolar Depression", "Escitalopram for Depression", "Pharmacoeconomics of SSRIs for Depression", " Depression in Patients with Cardiovascular Disease", "Pharmacological Treatment Strategies of Depression", "SSRIs for Depression in Diabetes Patients", "SSRIs for Depression with Cognitive Impairment", "SSRIs for Depression in in Epileptic Patients", "SSRIs for Depression in Parkinsons Patients", "Geriatric Depression", "Agomelatin for Depression", "SSRIs and Augmentation for Treatment Resistant Depression", "Depression Treatment in Hepatitis Patients", "SSRIs for Depression after Traumatic Brain Injury", "Sex differences in SSRI Response", "SRRIs and Ocular Safety", "Transcranial Direct Current Stimulation (tDCS) for Depression", "SSRIs for Depression in Cancer", "SSRIs for Dysthymia", "SSRIs for Postpartum Depression", "St. John's Wort for Depression", "SSRIs for Depression in Kidney Disease Patients", "SSRIs for Depression in Kidney Disease Patients", "Predicting SSRI Response in Depression via miRNA and BDNF", "Vilazodone for Depression", "SSRIs for the Mangement of Multiple Sclerosis", "Folate for Depression", "SSRIs for Depression in Chronic Obstructive Pulmonary Disease (COPD) Patients", "SSRIs Effect on Brain-derived Neurotrophic Factor (BDNF) Levels in Depressive Patients", "SSRIs for Depression in HIV-positive Patients", "Loudness Dependence of Auditory Evoked Potentials (LDAEP) as Biomarker for Depression", "Olfactory Bulbectomized (OB) Rat Model of Depression", "Tryptophan Depletion in Depression"], "Anxiety": ["SSRIs Effect on Fear", "SSRIs for Panic Disorder", "SSRIs for Generalized Anxiety Disorder (GAD)", "SSRIs for Social Anxiety Disorder", "SSRIs for Pediatric Anxiety"], "Weight and Eating Disorders": ["SSRIs for Weight Management", "SSRIs for Eating Disorders"], "Substance Abuse/Addictions": ["SSRIs for Alcohol Dependence", "SSRIs for Substance Abuse (Cocaine)", "SSRIs for Behavioral Addictions", "SSRIs for Smoking Cessation"], "Other": ["SSRIs for Obsessive-Compulsive Disorder (OCD)", "SSRIs for PTSD", "SSRIs in Dementias", "SSRIs for Pain", "SSRIs for (Psycho)dermatological Diseases", "SSRIs Effect on Sleep", "Fluvoxamine for Covid 19", "Premature Ejaculation", "SSRIs for Premenstrual Dysphoric Disorder (PMDD)", "SSRIs for Irritable Bowel Syndrome", "Menopausal Vasomotor Symptoms (Hot flashes)", "SSRIs for Borderline Personality Disorder", "SSRIs for Autism Spectrum Disorders", "SSRIs (Fluvoxamine) for Schizophrenia", "SSRIs Effect on Pulmonary Hypertension", "SSRIs for Body Dysmorphic Disorder (BDD)", "SSRIs for Fibromyalgia", "Risk for Orofacial Pain Disorders", "SSRIs for Enuresis", "SSRIs for Migraine", "SSRIs for Trichotillomania", "SSRIs for Congenital Myasthenic Syndrome (SCCMS)", "SSRIs in the Treatment of Huntington Disease", "SSRIs for Tinnitus ", "SSRIs for Syncope"]}}, "Safety": {"Special Populations": {"Pediatrics": ["Pediatric Depression", "SSRIs for Pediatric Anxiety"], "Geriatrics": ["SSRIs in Dementias", "Fracture Risk", "SSRIs for Depression with Cognitive Impairment", "SSRIs for Depression in Parkinsons Patients", "Harmful Drug Interactions", "Hyponatremia Risk", "Geriatric Depression"], "Other": ["Post-Stroke SSRI Use", " Depression in Patients with Cardiovascular Disease", "SSRIs for Depression in Diabetes Patients", "SSRIs for Depression in in Epileptic Patients", "Depression Treatment in Hepatitis Patients", "SSRIs for Depression after Traumatic Brain Injury", "SSRIs for Depression in Cancer", "SSRIs for Depression in Kidney Disease Patients", "SSRIs for the Mangement of Multiple Sclerosis", "SSRIs for Depression in Chronic Obstructive Pulmonary Disease (COPD) Patients", "SSRIs for Depression in HIV-positive Patients"]}, "Perinatal Exposure": ["Risks of Prenatal Exposure", "Risk of Perinatal Exposure (Rodents)", "SSRIs for Postpartum Depression"], "Suicide": ["The Chronic Unpredictable Mild Stress Model of Depression", "Suicice Risk"], "Sexual Dysfunction": ["Sexual Dysfunction", "SSRIs Effect on Male Fertility"], "Toxicity": ["Serotonin Syndrome", "Methylenedioxymethamphetamine (MDMA) Induced Neurotoxicity", "Forensic Drug Concentration", "Hepatotoxic Risk"], "Other": ["Bleeding Risk", "QTC Prolongation", "Oncopreventive and Oncolytic Properties of SSRIs", "Extrapyramidal Reactions Risk", "SSRIs for Social Anxiety Disorder", "SSRI Safety Reviews", "Withdrawal Symptoms", "Repeated SSRIs Exposures Effects on Dopamine Receptors", "Hyperprolactinemia-related Symptoms", "SRRIs and Ocular Safety", "Risk for Orofacial Pain Disorders", "Risk of Hallucinations"]}, "Other": {"Ecotoxicology": ["Aquatic Ecotoxicology", "Environmental Degradation of Antidepressants"], "Alternative Treatments": ["Antidepressant-like Effects of Herbal Extracts in Animal Models", "St. John's Wort for Depression"], "Other": ["SSRI Utilization Patterns", "Pharmacoeconomics of SSRIs for Depression", "Menopausal Vasomotor Symptoms (Hot flashes)", "Canine Behavioral Disorders", "Generic SSRIs", "Critical Psychiatry"]}}